Ian F Hermans

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6025122/publications.pdf

Version: 2024-02-01

94 papers	4,221 citations	117571 34 h-index	118793 62 g-index
100 all docs	100 docs citations	100 times ranked	5448 citing authors

#	Article	IF	Citations
1	Tumour infiltrating lymphocyte density differs by meningioma type and is associated with prognosis in atypical meningioma. Pathology, 2022, , .	0.3	2
2	6â€³-Modifed Î±-GalCer-peptide conjugate vaccine candidates protect against liver-stage malaria. RSC Chemical Biology, 2022, 3, 551-560.	2.0	7
3	Intratumoural administration of an NKT cell agonist with CpG promotes NKT cell infiltration associated with an enhanced antitumour response and abscopal effect. OncoImmunology, 2022, 11, .	2.1	7
4	Glycolipidâ€peptide conjugate vaccines elicit <scp>CD8</scp>⁺ Tâ€cell responses and prevent breast cancer metastasis. Clinical and Translational Immunology, 2022, 11, .	1.7	12
5	Using agonists for iNKT cells in cancer therapy. Molecular Immunology, 2021, 130, 1-6.	1.0	12
6	Tumour Hypoxia-Mediated Immunosuppression: Mechanisms and Therapeutic Approaches to Improve Cancer Immunotherapy. Cells, 2021, 10, 1006.	1.8	45
7	Harnessing NKT cells for vaccination. Oxford Open Immunology, 2021, 2, .	1.2	3
8	MR1â€dependent immune surveillance of the skin contributes to pathogenesis and is a photobiological target of UV light therapy in a mouse model of atopic dermatitis. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 3155-3170.	2.7	10
9	Mucosal-Associated Invariant T (MAIT) Cell Dysfunction and PD-1 Expression in Prostate Cancer: Implications for Immunotherapy. Frontiers in Immunology, 2021, 12, 748741.	2.2	7
10	The Chemical Synthesis, Stability, and Activity of MAIT Cell Prodrug Agonists That Access MR1 in Recycling Endosomes. ACS Chemical Biology, 2020, 15, 437-445.	1.6	24
11	MÄ•nuka honey-derived methylglyoxal enhances microbial sensing by mucosal-associated invariant T cells. Food and Function, 2020, 11, 5782-5787.	2.1	12
12	Modulating the Tumour Microenvironment by Intratumoural Injection of Pattern Recognition Receptor Agonists. Cancers, 2020, 12, 3824.	1.7	14
13	The Synthesis and Antiâ€tumour Properties of Poly Ethoxy Ethyl Glycinamide (PEEâ˜G) Scaffolds with Multiple PDâ€1 Peptides Attached. ChemMedChem, 2020, 15, 1128-1138.	1.6	4
14	Glycolipid-peptide vaccination induces liver-resident memory CD8 ⁺ T cells that protect against rodent malaria. Science Immunology, 2020, 5, .	5.6	43
15	Highâ€Dimensional Data Analysis Algorithms Yield Comparable Results for Mass Cytometry and Spectral Flow Cytometry Data. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2020, 97, 824-831.	1.1	27
16	Third-generation anti-CD19 chimeric antigen receptor T-cells incorporating a TLR2 domain for relapsed or refractory B-cell lymphoma: a phase I clinical trial protocol (ENABLE). BMJ Open, 2020, 10, e034629.	0.8	26
17	Vaccines adjuvanted with an NKT cell agonist induce effective T-cell responses in models of CNS lymphoma. Immunotherapy, 2020, 12, 395-406.	1.0	10
18	Distinct Dysfunctional States of Circulating Innate-Like T Cells in Metabolic Disease. Frontiers in Immunology, 2020, 11, 448.	2.2	9

#	Article	IF	Citations
19	High-dimensional analysis of intestinal immune cells during helminth infection. ELife, 2020, 9, .	2.8	25
20	Enhancing T cell responses and tumour immunity by vaccination with peptides conjugated to a weak NKT cell agonist. Organic and Biomolecular Chemistry, 2019, 17, 1225-1237.	1.5	10
21	Local and global anisotropy - recent re-implementation of 2D ILT diffusion methods. Microporous and Mesoporous Materials, 2018, 269, 71-74.	2.2	3
22	Blocking CTLA-4 while priming with a whole cell vaccine reshapes the oligoclonal T cell infiltrate and eradicates tumors in an orthotopic glioma model. OncoImmunology, 2018, 7, e1376154.	2.1	22
23	Increased Efficacy of NKT Cell-Adjuvanted Peptide Vaccines Through Chemical Conjugation. , 2018, , 309-335.		1
24	A phase I vaccination study with dendritic cells loaded with NY-ESO-1 and Î±-galactosylceramide: induction of polyfunctional T cells in high-risk melanoma patients. Cancer Immunology, Immunotherapy, 2018, 67, 285-298.	2.0	49
25	Langerin+ CD8Î±+ Dendritic Cells Drive Early CD8+ T Cell Activation and IL-12 Production During Systemic Bacterial Infection. Frontiers in Immunology, 2018, 9, 953.	2.2	7
26	Stability of polyelectrolyte-coated iron nanoparticles for T 2 -weighted magnetic resonance imaging. Journal of Magnetism and Magnetic Materials, 2017, 439, 251-258.	1.0	18
27	Engaging Natural Killer T Cells as â€˜Universal Helpersâ€™ for Vaccination. Drugs, 2017, 77, 1-15.	4.9	29
28	Augmenting Influenza-Specific T Cell Memory Generation with a Natural Killer T Cell-Dependent Glycolipidâ€“Peptide Vaccine. ACS Chemical Biology, 2017, 12, 2898-2905.	1.6	27
29	Activation of Human Mucosal-Associated Invariant T Cells Induces CD40L-Dependent Maturation of Monocyte-Derived and Primary Dendritic Cells. Journal of Immunology, 2017, 199, 2631-2638.	0.4	96
30	Determining mean fractional anisotropy using DDCOSY: preliminary results in biological tissues. Magnetic Resonance in Chemistry, 2017, 55, 498-507.	1.1	13
31	Effects of treatment changes on asthma phenotype prevalence and airway neutrophil function. BMC Pulmonary Medicine, 2017, 17, 169.	0.8	18
32	Whole tumor cell vaccines for glioma immunotherapy. Immunotherapy, 2016, 8, 387-389.	1.0	3
33	Poly Ethoxy Ethyl Glycinamide (PEEâ€G) Dendrimers: Dendrimers Specifically Designed for Pharmaceutical Applications. ChemMedChem, 2016, 11, 1583-1586.	1.6	6
34	Splenic Dendritic Cells Involved in Cross-Tolerance of Tumor Antigens Can Play a Stimulatory Role in Adoptive T-Cell Therapy. Journal of Immunotherapy, 2015, 38, 321-329.	1.2	6
35	Expression of CD1a and Type-1 Polarization Are Dissociated in Human Monocyte-Derived Dendritic Cells. PLoS ONE, 2015, 10, e0140432.	1.1	2
36	Dendritic cell vaccination combined with temozolomide retreatment: results of a phase I trial in patients with recurrent glioblastoma multiforme. Journal of Neuro-Oncology, 2015, 121, 319-329.	1.4	52

#	Article	IF	Citations
37	Enhanced immunosuppression by therapyâ€exposed glioblastoma multiforme tumor cells. International Journal of Cancer, 2015, 136, 2566-2578.	2.3	38
38	An adjuvanted whole cell vaccine as post-remission immunotherapy for acute leukemia. OncoImmunology, 2015, 4, e995568.	2.1	1
39	Activated NKT Cells Can Condition Different Splenic Dendritic Cell Subsets To Respond More Effectively to TLR Engagement and Enhance Cross-Priming. Journal of Immunology, 2015, 195, 821-831.	0.4	18
40	NKT cell-dependent glycolipidâ€“peptide vaccines with potent anti-tumour activity. Chemical Science, 2015, 6, 5120-5127.	3.7	64
41	Synthesis and Activity of 6â€³-Deoxy-6â€³-thio-Î±-GalCer and Peptide Conjugates. Organic Letters, 2015, 17, 5954-5957.	2.4	32
42	Batf3-independent langerinâ^' CX3CR1â^' CD8Î±+ splenic DCs represent a precursor for classical cross-presenting CD8Î±+ DCs. Journal of Leukocyte Biology, 2014, 96, 1001-1010.	1.5	15
43	A self-adjuvanting vaccine induces cytotoxic T lymphocytes that suppress allergy. Nature Chemical Biology, 2014, 10, 943-949.	3.9	70
44	Sustained in vivo depletion of splenic langerin+ CD8Î±+ dendritic cells is well-tolerated by lang-DTREGFP mice. Journal of Immunological Methods, 2014, 406, 104-109.	0.6	9
45	An autologous leukemia cell vaccine prevents murine acute leukemia relapse after cytarabine treatment. Blood, 2014, 124, 2953-2963.	0.6	24
46	Efficient depletion of chronic lymphocytic leukemia B cells using serial rounds of immunomagnetic depletion. Journal of Immunological Methods, 2013, 396, 152-156.	0.6	0
47	The control of CD8+T cell responses is preserved in perforin-deficient mice and released by depletion of CD4+CD25+regulatory T cells. Journal of Leukocyte Biology, 2013, 94, 825-833.	1.5	4
48	Identifying leukocyte populations in fresh and cryopreserved sputum using flow cytometry. Cytometry Part B - Clinical Cytometry, 2013, 84B, 104-113.	0.7	16
49	Exploiting invariant NKT cells to promote T-cell responses to cancer vaccines. OncoImmunology, 2013, 2, e23789.	2.1	18
50	Functional invariant natural killer T-cell and CD1d axis in chronic lymphocytic leukemia: implications for immunotherapy. Haematologica, 2013, 98, 376-384.	1.7	32
51	Using Magnetic Resonance Imaging to Evaluate Dendritic Cell-Based Vaccination. PLoS ONE, 2013, 8, e65318.	1.1	17
52	Strongly Magnetic Iron Nanoparticles Improve the Diagnosis of Small Tumours in the Reticuloendothelial System by Magnetic Resonance Imaging. PLoS ONE, 2013, 8, e56572.	1.1	12
53	Immature murine NKT cells pass through a stage of developmentally programmed innate IL-4 secretion. Journal of Leukocyte Biology, 2012, 92, 999-1009.	1.5	17
54	Vaccination with Irradiated Tumor Cells Pulsed with an Adjuvant That Stimulates NKT Cells Is an Effective Treatment for Glioma. Clinical Cancer Research, 2012, 18, 6446-6459.	3.2	47

#	Article	IF	Citations
55	Speciesâ€Specific Activity of Glycolipid Ligands for Invariant NKT Cells. ChemBioChem, 2012, 13, 1349-1356.	1.3	25
56	Synthesis and Stability of Highly Crystalline and Stable Iron/Iron Oxide Core/Shell Nanoparticles for Biomedical Applications. ChemPlusChem, 2012, 77, 135-140.	1.3	37
57	Virus-like particles and Î±-galactosylceramide form a self-adjuvanting composite particle that elicits anti-tumor responses. Journal of Controlled Release, 2012, 159, 338-345.	4.8	34
58	Hot-injection synthesis of iron/iron oxide core/shell nanoparticles for T2 contrast enhancement in magnetic resonance imaging. Chemical Communications, 2011, 47, 9221.	2.2	58
59	MIS416, a non-toxic microparticle adjuvant derived from Propionibacterium acnes comprising immunostimulatory muramyl dipeptide and bacterial DNA promotes cross-priming and Th1 immunity. Vaccine, 2011, 29, 545-557.	1.7	41
60	Exploiting the Role of Endogenous Lymphoid-Resident Dendritic Cells in the Priming of NKT Cells and CD8+ T Cells to Dendritic Cell-Based Vaccines. PLoS ONE, 2011, 6, e17657.	1.1	30
61	An improved synthesis of dansylated Î±-galactosylceramide and its use as a fluorescent probe for the monitoring of glycolipid uptake by cells. Carbohydrate Research, 2011, 346, 914-926.	1.1	29
62	Side Population is Not Necessary or Sufficient for a Cancer Stem Cell Phenotype in Glioblastoma Multiforme. Stem Cells, 2011, 29, 452-461.	1.4	97
63	RÃ¼cktitelbild: Simple Synthesis and Functionalization of Iron Nanoparticles for Magnetic Resonance Imaging (Angew. Chem. 18/2011). Angewandte Chemie, 2011, 123, 4110-4110.	1.6	0
64	Simple Synthesis and Functionalization of Iron Nanoparticles for Magnetic Resonance Imaging. Angewandte Chemie - International Edition, 2011, 50, 4206-4209.	7.2	148
65	Back Cover: Simple Synthesis and Functionalization of Iron Nanoparticles for Magnetic Resonance Imaging (Angew. Chem. Int. Ed. 18/2011). Angewandte Chemie - International Edition, 2011, 50, 4024-4024.	7.2	0
66	Administration of Î±-galactosylceramide impairs the survival of dendritic cell subpopulations in vivo. Journal of Leukocyte Biology, 2011, 89, 753-762.	1.5	8
67	Potent antiâ€tumor responses to immunization with dendritic cells loaded with tumor tissue and an NKT cell ligand. Immunology and Cell Biology, 2010, 88, 596-604.	1.0	33
68	Tumor Antigen Presentation by Dendritic Cells. Critical Reviews in Immunology, 2010, 30, 345-386.	1.0	51
69	Invariant natural killer T cells and asthma: Immunologic reality or methodologic artifact?. Journal of Allergy and Clinical Immunology, 2010, 126, 882-885.	1.5	17
70	Targeting Antigen to MHC Class II Molecules Promotes Efficient Cross-Presentation and Enhances Immunotherapy. Journal of Immunology, 2009, 182, 1260-1269.	0.4	37
71	Glycolipids Injected into the Skin Are Presented to NKT Cells in the Draining Lymph Node Independently of Migratory Skin Dendritic Cells. Journal of Immunology, 2009, 182, 7644-7654.	0.4	16
72	Langerin+CD8Î±+ Dendritic Cells Are Critical for Cross-Priming and IL-12 Production in Response to Systemic Antigens. Journal of Immunology, 2009, 183, 7732-7742.	0.4	84

#	Article	IF	Citations
73	Dendritic Cells Treated with Lipopolysaccharide Up-Regulate Serine Protease Inhibitor 6 and Remain Sensitive to Killing by Cytotoxic T Lymphocytes In Vivo. Journal of Immunology, 2008, 181, 8356-8362.	0.4	19
74	Tumor Immunotherapy by Epicutaneous Immunization Requires Langerhans Cells. Journal of Immunology, 2008, 180, 1991-1998.	0.4	88
75	Increasing the Survival of Dendritic Cells In Vivo Does Not Replace the Requirement for CD4+ T Cell Help during Primary CD8+ T Cell Responses. Journal of Immunology, 2007, 179, 5738-5747.	0.4	12
76	Dendritic Cell Function Can Be Modulated through Cooperative Actions of TLR Ligands and Invariant NKT Cells. Journal of Immunology, 2007, 178, 2721-2729.	0.4	82
77	5,6â€Dimethylxanthenoneâ€4â€acetic acid treatment of a nonâ€immunogenic tumour does not synergize with active or passive CD8 + Tâ€cell immunotherapy. Immunology and Cell Biology, 2006, 84, 383-389.	1.0	12
78	Novel synthesis of Î±-galactosyl-ceramides and confirmation of their powerful NKT cell agonist activity. Carbohydrate Research, 2006, 341, 2785-2798.	1.1	48
79	Autologous dendritic cells pulsed with eluted peptide as immunotherapy for advanced B-cell malignancies. Leukemia and Lymphoma, 2006, 47, 675-682.	0.6	8
80	Perforin-dependent elimination of dendritic cells regulates the expansion of antigen-specific CD8+ T cells in vivo. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 147-152.	3.3	121
81	CpG-matured Murine Plasmacytoid Dendritic Cells Are Capable of In Vivo Priming of Functional CD8 T Cell Responses to Endogenous but Not Exogenous Antigens. Journal of Experimental Medicine, 2004, 199, 567-579.	4.2	171
82	Utilizing the adjuvant properties of CD1d-dependent NK T cells in T cellâ€“mediated immunotherapy. Journal of Clinical Investigation, 2004, 114, 1800-1811.	3.9	150
83	Dendritic cells: a journey from laboratory to clinic. Nature Immunology, 2004, 5, 7-10.	7.0	194
84	The VITAL assay: a versatile fluorometric technique for assessing CTL- and NKT-mediated cytotoxicity against multiple targets in vitro and in vivo. Journal of Immunological Methods, 2004, 285, 25-40.	0.6	156
85	Utilizing the adjuvant properties of CD1d-dependent NK T cells in T cellâ€“mediated immunotherapy. Journal of Clinical Investigation, 2004, 114, 1800-1811.	3.9	77
86	High Avidity Antigen-Specific CTL Identified by CD8-Independent Tetramer Staining. Journal of Immunology, 2003, 171, 5116-5123.	0.4	85
87	NKT Cells Enhance CD4+ and CD8+ T Cell Responses to Soluble Antigen In Vivo through Direct Interaction with Dendritic Cells. Journal of Immunology, 2003, 171, 5140-5147.	0.4	445
88	Synergistic effect of metronomic dosing of cyclophosphamide combined with specific antitumor immunotherapy in a murine melanoma model. Cancer Research, 2003, 63, 8408-13.	0.4	107
89	Competition Between CTL Narrows the Immune Response Induced by Prime-Boost Vaccination Protocols. Journal of Immunology, 2002, 168, 4391-4398.	0.4	145
90	Killing of Dendritic Cells. Journal of Experimental Medicine, 2001, 194, F23-F26.	4.2	67

#	Article	IF	Citations
91	Dendritic cell elimination as an assay of cytotoxic T lymphocyte activity in vivo. Journal of Immunological Methods, 2000, 246, 109-117.	0.6	50
92	CD8+ T Cell-Dependent Elimination of Dendritic Cells In Vivo Limits the Induction of Antitumor Immunity. Journal of Immunology, 2000, 164, 3095-3101.	0.4	208
93	Cytotoxic T Lymphocyteâ€“associated Antigen 4 (CTLA-4) Can Regulate Dendritic Cellâ€“induced Activation and Cytotoxicity of CD8+ T Cells Independently of CD4+T Cell Help. Journal of Experimental Medicine, 1999, 189, 1157-1162.	4.2	64
94	Tumor-peptide-pulsed dendritic cells isolated from spleen or cultured in vitro from bone marrow precursors can provide protection against tumor challenge. Cancer Immunology, Immunotherapy, 1997, 44, 341-347.	2.0	44